LES 2004 Winter Meeting: Licensing Converging Technologies - Bridging the Gap February 11-13 | Westin St. Francis San Francisco, CA

Download Winter Meeting Registration Brochure Welcome Letter from Meeting Chairs Meeting Committee Meeting Program: Schedule Add-on Seminars Plenary Sessions Workshops Tech Fair LES Professional Development Series (PDS): Fundamentals of Intellectual Asset Management PDS Workshops Registration: Registration Info Register Today! Sponsors Miscellaneous Info Westin St. Francis Social Events Weather and Dress

Speaker Biographies Joe Boeddeker Joseph J. Brindisi Ken Buckingham Linda Chao Mary Lynn Coyle Q. Todd Dickinson Mark G. Edwards Fred Farina Donald Featherstone Jennifer Fonstad Donna Hamlin Linda C. Hogan Mark S. Holmes Damon C. Matteo Christine Mayer Joseph S. McCracken Arlene M. Morris Matthew Murphy Robert A. Morrison Deborah Rozman Craig Smith Michael Specht Philip Summa Randall B. Sunberg Maya Tanaka William C. Torch Lawrence J. Udell John R. Wetherell Charles R. Williams Dr. Michael Wynblatt Joe Boeddeker Mr. Boeddeker has been active in the entrepreneurial arena for the last twenty-Four years. He is currently President and CEO of The Venture Growth Alliance (VGA); an international collaborative organization assisting venture development and technology transfer efforts. Prior to co-founding The Venture Growth Alliance, he served in the dual role as President and CEO of The Enterprise Network (TEN) and Director of the NASA/Ames Technology Commercialization Center (ATCC). Under his leadership, this not-for-profit organization became the leading example of a successful incubator and network of entrepreneurial advisors, practices, facilities and services, and was proactive in launching over 200 new ventures. Mr. Boeddeker cultivated networks of international scope within the academic, investor, corporate and government communities. In addition, he created the Academic Bridge Program providing graduate level college students from prominent universities across the country with internships working with new ventures. In 1999, The New York Times described The Enterprise Network as the primo incubator in the nation. The Public Broadcasting System ran an international special on its achievements, and Ernst and Young gave Mr. Boeddeker the distinguished honor of Entrepreneur of the Year. In 1999 he was also inducted into U.S. Entrepreneurial Hall of Fame. Previous to his work at TEN, Mr. Boeddeker was a full time mentor to start-up ventures in Silicon Valley. Earlier in his career, he founded four companies. He received his corporate experience in a variety of executive roles with Raychem Corporation of Menlo Park, California during twelve years of rapid growth from $38 million to over $1B. Mr. Boeddeker sits as a director or board member on many start-up ventures and other entrepreneurial related organizations to include: The Entrepreneurial Business Cluster, Los Alamos National Laboratory (DOE), Siemens Technology to Business Center, The Foundation for Educational Achievement, Cogswell Polytechnic College and The University of Illinois. Mr. Boeddeker attended The University of San Francisco, The United States Naval Academy and Santa Clara University. Joseph J. Brindisi Joseph J. Brindisi is General Counsel and Vice President of Business Development, Kyowa Pharmaceutical, Inc. and is responsible for helping define the globalization strategy for the pharmaceutical business and product pipeline of Kyowa. Joe has also worked with Kyowa Hakko to found a new U.S. incorporated and based Biotech Company called BioWa. BioWa is the exclusive licensee of a new-generation platform technology developed by Kyowa Hakko (i.e. Potelligentª Technology) that can maximize the value of therapeutic monoclonal antibodies (mAb) for BioWa and its Biotech partners. Ken Buckingham Ken Buckingham has been employed as a software engineer at IBM for twenty-three years, working in diverse areas such as project management, software development, technical marketing and education. He has taught technical classes to IBM customers and IBMers on every continent. Having followed the developing field of nanotechnology since 1974 and encouraged by the White House's January 2000 announcement of its National Nanotechnology Initiative, he founded Tiny Technology, Inc., a company which offers nanotechnology consulting and a distance learning course via a highly-accredited midwestern university. He has spoken publicly on the subject of nanotechnology since 2000. Ken's interest and pursuit of for-profit education in the U.S. includes serving on the Advisory Council of National American University. Linda Chao Linda Chao is a Licensing Associate in Stanford University's Office of Technology Licensing and a registered patent agent. She manages a portfolio of over 300 inventions, including photonic, semiconductor, nanotechnology, communication, and bioengineering technologies, and negotiates licenses with companies ranging from start-up ventures to Fortune 500 companies. She is also the OTL representative to the Stanford Entrepreneurship Network. Her technical and business experience includes microprocessor design at Digital Equipment Corporation, industry analysis at SEMATECH, and product marketing at Applied Materials. Linda received a Bachelor of Science in Electrical Engineering, a Master of Science in Electrical Engineering, and a Master of Science in Management from Massachusetts Institute of Technology. Mary Lynn Coyle Mary Lynn Coyle is communications executive and consultant with experience in professional services, information and high technology, industrial and consumer products, healthcare and education. She has directed branding, communications and marketing activities in more than 20 countries and her programs have won almost 50 international, national and local communications awards. Q. Todd Dickinson Q. Todd Dickinson is a Partner in the law firm of Howrey Simon Arnold & White, where he is a leader in its Intellectual Property Practice Group. He has more than twenty-five years of experience in all aspects of intellectual property law and public policy, including patents, trademarks, copyrights, and trade secrets. Prior to joining Howrey, Mr. Dickinson was Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office (USPTO), having been nominated by President Clinton and confirmed by the U.S. Senate. At the USPTO, Mr. Dickinson implemented the electronic filing of patent and trademark applications, broke ground for the new 2 million sq. ft. PTO Campus, made all USPTO patents and trademark registrations freely available over the Internet, and lead the implementation by the USPTO of the most sweeping revisions to patent law and practice in over 50 years. In his role as Under Secretary, he was principal policy advisor to the President on all intellectual property matters, as well as representing the U.S. government internationally in IP matters, including serving as the Chief Negotiator on behalf of the United States for the Patent Law Treaty (2000), the Trademark Law Treaty (1999) and the revisions to the Hague Agreement on Industrial Design (1999). Mr. Dickinson has written and spoken extensively on intellectual property issues, especially those affecting emerging technologies, and has testified before Congress, the Federal Trade Commission and the National Academy of Sciences on the impact of IP policies. He has also taught or lectured at various universities including Stanford, Yale, Berkeley, MIT, Georgetown, George Washington and Tokyo University. Mr. Dickinson is a member a number of intellectual property organizations, including the American Bar Association and its Intellectual Property Law Section, where he chairs the Patent System Policy Planning Committee and is the Delegate to the World Intellectual Property Organization. He is also a Board member of the Licensing Executive Society Foundation. He earned his J.D. in 1977 from University of Pittsburgh and his B.S. from Allegheny College in 1974. He is admitted to the bars of the District of Columbia, Pennsylvania, Illinois and California, United States Patent and Trademark Office, and the Court of Appeals for the Federal Circuit. Mark G. Edwards Mark G. Edwards is the Managing Director of Recombinant Capital, Inc. (Recap), a consulting firm based in Walnut Creek, California. More than 500 biotechnology, pharmaceutical and service companies subscribe to ReCap's databases (Recap.com & rDNA.com) or retain Recap to advise on biotech alliances and valuations. Mr. Edwards is on the Board of Directors of Allos Therapeutics, Inc. Prior to founding ReCap in 1988, Mr. Edwards was Manager of Business Development at Chiron Corporation. He received his B.A. and M.B.A. degrees from Stanford University. Fred Farina Fred Farina is Assistant Director of Technology Transfer at the California Institute of Technology. Fred's responsibilities include evaluating inventions at Caltech and the Jet Propulsion Laboratory, making patent filing decisions, supervising patent prosecution, managing the patent portfolio, negotiating licensing deals and assisting inventors with the creation of startup companies. Prior to joining the office, Fred worked for eight year as a Research Engineer in the GPS field. He subsequently joined a law firm where he prosecuted patent applications on various electrical technologies before the US and European Patent Offices. Fred holds a "Diplôme d'Ingénieur" in Electrical Engineering from the National Institute of Applied Sciences, Lyon, France, and is a graduate of Caltech from which he received his M.S. in Electrical Engineering. He is registered to practice before the U.S. Patent and Trademark Office. Donald Featherstone Mr. Featherstone is a director in the electrical practice group of Sterne, Kessler, Goldstein & Fox P.L.L.C. and is a co-chairman of the firm's nanotechnology practice group. In addition to strategic patent portfolio creation and management, Mr. Featherstone prepares opinions, technology agreements, IP audits and performs due diligence investigations. He is a former patent examiner of semiconductor devices. Mr. Featherstone received his J.D., Intellectual Property Law Specialty Track, from the George Mason University and a B.S. in Electrical Engineering from Lafayette College. Jennifer Fonstad Jennifer Fonstad is a Managing Director of Draper Fisher Jurvetson, an early stage information technology venture firm. She currently sits on several private company boards, including Natero, a start-up building carbon nanotube-based DRAM, Troika Networks, a storage area networking firm, NanoCoolers, a chip cooling vendor, and IPedo, a software-based data cache solution. She also led the firm's investment in Molecular Imprints, a nano-imprint lithographer, Luminus Devices, a solid state lighting company, Ember, a wireless mesh network solution, and Athenahealth, an eHealth services vendor. She began her career with Bain and Company after spending a year teaching in sub-Sahara Africa. Ms. Fonstad holds a B.S. cum laude from Georgetwon University and an MBA with Distinction from the Harvard Business School. She is a former Kauffman Fellow. Donna Hamlin Donna Hamlin is Chief Executive Officer and Board Chair for Hamlin Harkins, Ltd., founded in 1982. The consultancy supports companies from Fortune 500 global enterprises to start-up companies in more than 30 countries with strategic planning, financial management, mergers, acquisitions, organization development, human resource planning, new product development, marketing and research. Linda C. Hogan Linda C. Hogan is Vice President, Business Development of Clearview Projects in Princeton, New Jersey. Clearview Projects is an innovative company providing biopharmaceutical companies with transaction-oriented deal planning, preparation, and execution. Linda has nearly 20 years of experience working in major pharmaceutical companies, including her recent responsibilities as Vice President, US Group Head, Global Business Development at Aventis. She was responsible for identifying, evaluating, and negotiating licensing opportunities for Aventis as well as managing the US Office of Global Business Development. She began her career in the pharmaceutical industry as a senior scientist in the medical affairs department at Marion Laboratories, Inc. Through a series of mergers, she held successive positions in strategic planning and licensing at Marion Merrell Dow Inc., Hoechst Marion Roussel and Aventis. Prior to joining Marion, Linda was an Assistant Professor and Director, Drug Information Service, at the University of Kansas School of Pharmacy and Hospital Medical Center. She holds both a BS and MS from University of Kansas School of Pharmacy and completed her residency of Hospital Pharmacy, University of Kansas Medical Center and Hospital. She received her MBA from Rockhurst College in Kansas City, Missouri. Mark S. Holmes Mark Holmes is the President and founder of the IP Venture Group. He is an AV-rated patent attorney who specializes in the business aspects of patent and technology commercialization and technology deal-making. He speaks nationally on intellectual property and is the author of the book PATENT LICENSING: NEGOTIATION, STRATEGY AND FORMS. Damon C. Matteo Over the course of his fifteen-year international career in intellectual capital management and commercialization, Damon C. Matteo acquired extensive experience in the full-spectrum management of corporate intellectual capital assets: from optimizing their creation and capture, to extracting value through vehicles such as licensing, spin-outs and assertion. Currently Vice President of the Palo Alto Research Center, Damon directs all aspects of PARC operation which touch IP: including research targeting, strategic management of IP assets, IP administration, legal operations and on the commercialization side such vehicles as licensing, spin-outs and assertions. Previously at Hewlett-Packard, Damon was brought in to create from scratch and manage a world-class licensing organization responsible for all Hewlett-Packard licensing. Damon's experience is also international, having lived and worked in both Europe and Asia. Damon is also the recipient a number of national awards, serves as a Fellow at the Center For Advanced Technology and is on the Board of the European Center For Intellectual Property Studies. Christine Mayer Christine Mayer is a multi-disciplined executive, with over 20 years of broad business experience, of which 16 years were spent in the pharmaceutical industry across several disciplines and therapeutic areas. Christine currently holds the position of V.P./U.S. Group Head in Global Business Development at Aventis. She is responsible for managing a team of executives who suppot both U.S. and global efforts in all aspects of Business Development including licensing opportunities, divestitures, marketing alliances and other partnerships. Before joining Aventis, Christine worked for Johnson & Johnson for 13 years in the pharmaceutical sector. She has held many positions in various disciplines including Business Development, Marketing, Sales and Finance. Christine holds an M.B.A. in Finance from Rutgers University and a B.A. from Glassboro State College. Joseph S. McCracken Joseph S. McCracken joined Genentech, Inc. as Vice President, Business Development in July of 2000, with responsibility for Business Development, Licensing and Alliance Management activities. Currently, Vice President of Business and Commercial Development, Dr. McCracken is also responsible for International Operations, Market Research and Market Development at Genentech. Arlene M. Morris Arlene M. Morris joins Affymax, Inc. as President and Chief Executive Officer, bringing significant expertise in the development of strategic partnerships, marketing and operations to Affymax. Ms. Morris has over 25 years of management experience from Johnson & Johnson, Scios Inc., Coulter Pharmaceutical, Inc., Corixa Corporation and most recently Clearview Projects. From 1977 through 1993, Ms. Morris held various management and executive positions at Johnson & Johnson in sales, marketing and business development, holding the position of Vice President of Business Development for McNeil Pharmaceutical from 1988 to 1993. She is a member of the Board of Directors of the Licensing Executives Society and Affymax. Matthew Murphy Mr. Murphy is Vice President of Intellectual Property for Nanosys, Inc., a nanotechnology company developing inorganic nanomaterial based devices and systems. Prior to Nanosys, Mr. Murphy was Vice President of Intellectual Property for Caliper Technologies, where he built the dominant industry patent estate in the field of microfluidics. Prior to joining Caliper, Mr. Murphy was associated with the Law Firm of Townsend and Townsend and Crew, LLP, in the Chemical/Biotechnology Practice Group. He received his J.D. from the University of San Francisco, and his B.S. in Microbiology from University of California, Davis. Deborah Rozman Deborah Rozman, Ph.D., is President of Quantum Intech which licenses technologies "powered by HeartMath" to relieve stress, improve health and performance. Dr. Rozman is co-author of the books Overcoming Emotional Chaos and Transforming Anger and Best Practices Publication's Manage Organizational and Business Chaos for Exceptional Business Performance Results. Craig Smith Craig Smith is Sandia National Laboratories Commercial Licensing Manager for Emerging Technologies. Mr. Smith's primary focus is to develop key commercialization strategies for the Department of Energy's premier Combustion Research Facility, specializing in the fields of Renewable Energy Research, Industrial Processes, Engine Emissions and Hydrogen Fuel Cell Development. Mr. Smith is also responsible for the commercial licensing of all software related intellectual property, the development of the National Cyber Security program, and all commercial opportunities emerging from Sandia's new Distributed Information Systems Laboratory complex. Michael Specht Michael Specht is an associate in the electronics and nanotechnology practice groups of Sterne, Kessler, Goldstein & Fox P.L.L.C. In addition to strategic patent portfolio creation and management, he prepares opinions, technology agreements, IP audits and performs due diligence investigations. He was formerly general counsel of an early stage technology company, served as a Senior Engineer at the Federal Communications Commission and began his career at Telcordia Technologies. Mr. Specht received a J.D., cum laude, from Georgetown University, an M.S. in electrical engineering from Purdue University and a B.S. with highest honors from Case Western Reserve University. Philip Summa Philip Summa is a registered patent attorney with 20 years' experience in intellectual property law, and the founding partner of Summa & Allan, P.A., a specialized intellectual property firm in Charlotte, North Carolina. He holds a Bachelors Degree in Chemistry from Gettysburg College, a Masters Degree in Chemistry from North Carolina State University, and a Law Degree from Campbell University. He has served as Chair of the Intellectual Property Section of the North Carolina Bar Association. Mr. Summa is a member of the American Bar Association, the American Intellectual Property Law Association, the Licensing Executives Society, the Fourth Circuit Judicial Conference, and the American Chemical Society. From 1982 through 1997 he served as an Associate, Director and Shareholder for Bell Seltzer Park & Gibson. In 1997, Mr. Summa founded his present firm for the purpose of continuing an independent practice of intellectual property law in the Carolinas. In 2002, 2003 and 2004, Mr. Summa was named a member of "The Legal Elite" in Intellectual Property by Business North Carolina magazine. Randall B. Sunberg Randall B. Sunberg leads the life sciences transactions practice at Morgan Lewis, representing pharmaceutical, biotechnology and other life sciences companies in mergers and acquisitions, joint ventures, strategic alliances, collaborations and corporate partnering transactions. He graduated from New York University School of Law and Yale University. Maya Tanaka Maya Tanaka is Director of Business Development for Gemini Science, Inc., the San Diego-based wholly-owned US subsidiary of Kirin Brewery Co., Ltd. of Japan. Ms. Tanaka is involved in the identification and in-licensing of technologies complementary to Kirin's research and development efforts for the company's human antibody business which is based on Kirin's proprietary TC Mouse™ Technology Platform. Prior to joining Gemini, Ms. Tanaka held various research positions at Immulogic Pharmaceutical, Corp. and Genentech, Inc, and received her degree in Biochemistry from the University of California, Berkeley. William C. Torch, MD, MSc. Physician: U. Rochester, School of Medicine (MD), Intern, Resident, Fellow in Pediatrics & Child and Adult Neurology, Massachusetts General Hospital, Albert Einstein College of Medicine, University of British Columbia. Child & Adult Neurologist: Adjunct Professor, Former Assist. Prof., U. of Nevada, School of Medicine, Founder & current Medical Director, Neurodevelopmental and Neurodiagnostic Center, Reno, Nevada Sleep Specialist: Founder, current Medical Director, Washoe Sleep Disorders Center (Accredited by the American Academy of Sleep Medicine), Reno, Nevada. Researcher: Training at Brooklyn College, CUNY (B.S., Chemistry); U. Rochester, Center Brain Research & Dept. of Biochemistry, School of Medicine, (M.S., M.D., Bio-Chemistry); NIH/NIMH (Research Associate in Neurochemistry, LtCdr, USPHS, Lab Cerebral Metabolism). Inventor: President, Nevada Inventor's Association, Reno, Nevada; Founder and Chairman, Eye Com Corp. & Sleep Management, Inc.; Author, ÒA Children's Bill of Rights & A Declaration of Children's RightsÓ; Founder, Nevada Museum of Science, Technology & Industry (NMSTI) and Children's Science Exploratorium, Reno, Nevada. Robert A. Morrison For the past twenty years I have been involved in discovery, product and business development and marketing in the life sciences. I have been involved in the discovery, development, and market introduction of several products that currently generate significant sales. Prior to joining BTG, my responsibilities included global product and business development for a line of products derived from agricultural biotechnology. Upon coming to BTG, I assumed responsibility for a technology portfolio that included technology for several industries including animal health, agricultural biotechnology, crop protection and food. Lawrence J. Udell Lawrence J. Udell is Executive Director of both the Center For New Venture Alliance and the California Invention Center. He has created and taught "New Ventures and Entrepreneurship" courses for over 25 years, plus a special course on, "Technology Marketing" at the Cal-State Hayward, School of Business and Economics. He has served as a Lecturing Professor at U.C. Berkeley teaching a course on Technology Transfer & Commercialization, plus other universities in the U. S. and Canada. He is an active member of the Licensing Executives Society, and is co-founder and Managing Director of the Silicon Valley Chapter of LES. He also serves as Senior Consultant to General Patent Corporation of Suffern, NY. Founder of over 20 corporations, he also provides consulting to both start-ups and Fortune 500 companies. He lectures frequently at inventor, corporate and government functions throughout America and in other countries for the World Intellectual Property Organization (WIPO division of the United Nations). John R. Wetherell, PH.D., J.D. Dr. Wetherell has over 18 years experience in intellectual property law. His counseling experience includes intellectual property acquisition, transactional due diligence, patent infringement and validity analyses, freedom-to-operate opinions, as well as licensing and strategic counseling. Dr. Wetherell's patent prosecution experience includes obtaining U.S. and foreign protection in biotechnology areas such as molecular biology, immunology, nanotechnology, medical diagnostics, microbiology and pharmacology. He also evaluates intellectual property portfolios for both companies and investors. Dr. Wetherell received a B.S. degree in Chemistry, and a Ph.D. degree in Microbiology/ Immunology, both from the University of Florida, and a J.D. degree from Seton Hall School of Law. He conducted post-doctoral research, including studies on the humoral and cellular immune responses in periodontal disease, at Forsyth Dental Center in Boston, where he concurrently held an NIH post-doctoral fellowship and a Young Principal Investigator's award. Before becoming an attorney, he gained extensive experience as a research scientist and manager during his five-year tenure in the biotechnology industry. Dr. Wetherell is on the faculty of the University of California, San Diego, where he teaches courses in biotechnology patent law, strategy, and related transactional issues. He has written and lectured extensively for many organizations and institutions. In addition, he has lectured to a variety of groups around the world on topics related to patent law. Charles R. Williams, J.D., Ph.D. Dr. Williams is currently Director of the University of Washington's Office of Software & Copyright Ventures (OSCV). OSCV handles software, software patents, copyrighted works and other information assets with licensing generating $3.6 million in Fiscal 2003. The direct distribution of bioinformatics software for over seven years is one of the models OSCV uses to create distribution channels and develop industry relationships. Dr. Williams is currently implementing and working on the development of new technology transfer methods in the non-profit arena, including technology access programs for industry and the use of licensing to create and protect the academic information/research commons. He holds a M.Sc. in Biology from the University of Dundee, J.D. from the University of Washington Law School and a Ph.D. in Botany from the University of Washington. Dr. Michael Wynblatt Dr. Michael Wynblatt is Director of Venture Technology at Siemens Technology-to-Business Center (TTB), where he has responsibility for identifying and nurturing innovative technologies and building them into viable businesses. Michael's work at TTB has led to the commercialization by Centerboard Inc. of a novel distributedÊdata management technology, the commercialization by WhoGlue, Inc., of a novel personal relationship management technology, and the commercialization by Siemens Dematic of a novel distributed manipulation technology for parcel handling. Michael was a member of the founding team of TTB, and with particular responsibility for recruiting the innovation team and defining the key innovation spaces in which TTB would operate. Prior to joining TTB, he was a Member Technical Staff at Siemens Corporate Research in Princeton. He holds a Ph.D. in Computer Science from the State University of New York at Stony Brook, and a BSE in Computer Engineering from the University of Michigan. An accomplished inventor, Siemens has filed for 16 patents on Michael's work.